BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 10870124)

  • 21. Long-term results after allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic phase: a report from the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    van Rhee F; Szydlo RM; Hermans J; Devergie A; Frassoni F; Arcese W; de Witte T; Kolb HJ; Niederwiser D; Jacobsen N; Gahrton G; Bandini G; Carreras E; Bacigalupo A; Michallet M; Ruutu T; Reiffers J; Goldman JM; Apperley J; Gratwohl A
    Bone Marrow Transplant; 1997 Oct; 20(7):553-60. PubMed ID: 9337056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Qualitative assessment of mixed chimerism after allogeneic bone marrow transplantation with regard to leukemic relapse.
    Kögler G; Hernandez A; Heyll A; Wolf HH; Wernet P
    Cancer Detect Prev; 1996; 20(6):601-9. PubMed ID: 8939346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early prediction of molecular remission by monitoring BCR-ABL transcript levels in patients achieving a complete cytogenetic response after imatinib therapy for posttransplantation chronic myelogenous leukemia relapse.
    Kim YJ; Kim DW; Lee S; Min CK; Goh HG; Kim SH; Lee JY; Kim YL; Kim HJ; Kim HJ; Lee JW; Kim TG; Min WS; Kim CC
    Biol Blood Marrow Transplant; 2004 Oct; 10(10):718-25. PubMed ID: 15389438
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Frequent detection of BCR-ABL specific mRNA in patients with chronic myeloid leukemia (CML) following allogeneic and syngeneic bone marrow transplantation (BMT).
    Gaiger A; Lion T; Kalhs P; Mitterbauer G; Henn T; Haas O; Födinger M; Kier P; Forstinger C; Quehenberger P
    Leukemia; 1993 Nov; 7(11):1766-72. PubMed ID: 8231244
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
    Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
    Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
    DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
    Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Monitoring of minimal residual disease in patients with chronic myeloleukemia: clinical value of real-time polymerase chain reaction].
    Chelysheva EIu; Turkina AG; Misiurin AV; Aksenova EV; Domracheva EV; Zakharova AV; Khoroshko ND
    Ter Arkh; 2007; 79(4):49-53. PubMed ID: 17564019
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Significance of dynamic detection of WT1 expression on monitoring minimal residual disease in leukemia patients following allogeneic bone marrow transplantation].
    Gu WY; Chen ZX; Hu SY; Zhu J; Wang ZL; Yan F; Wang W; Cen JN; Shen HL; Qian J
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):444-7. PubMed ID: 15854547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal residual disease status in transplanted chronic myelogenous leukemia patients: low incidence of polymerase chain reaction positive cases among 48 long disease-free subjects who received unmanipulated allogeneic bone marrow transplants.
    Guerrasio A; Martinelli G; Saglio G; Rosso C; Zaccaria A; Rosti G; Testoni N; Ambrosetti A; Izzi T; Sessarego M
    Leukemia; 1992 Jun; 6(6):507-12. PubMed ID: 1602789
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients.
    Ballestrero A; Cirmena G; Dominietto A; Garuti A; Rocco I; Cea M; Moran E; Nencioni A; Miglino M; Raiola AM; Bacigalupo A; Patrone F
    Int J Lab Hematol; 2010 Aug; 32(4):387-91. PubMed ID: 19968720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study on relationship between different bcr/abl fusion transcripts and clinical manifestations in chronic myeloid leukemia].
    Qin YZ; Liu YR; Li JL; Wang H; Chang Y; Fu JY; Ruan GR; Qiu JY; Lu DP; Chen SS
    Zhonghua Xue Ye Xue Za Zhi; 2003 Jul; 24(7):347-50. PubMed ID: 12941187
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Use of quantitative polymerase chain reaction to monitor residual disease in chronic myelogenous leukemia during treatment with interferon.
    Lion T; Gaiger A; Henn T; Hörth E; Haas OA; Geissler K; Gadner H
    Leukemia; 1995 Aug; 9(8):1353-60. PubMed ID: 7643624
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Fate of chronic myeloid leukemia patients treated with allogeneic bone marrow transplantation or chemotherapy and/or interferon at a single center: long-term results.
    Gaziev D; Galimberti M; Polchi P; Angelucci E; Giardini C; Baronciani D; Andreani M; Persini B; Erer B; Sodani P; Manna M; Nicolini G; Visani G; Lucarelli G;
    Bone Marrow Transplant; 2002 Jan; 29(1):1-8. PubMed ID: 11840137
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The monitoring of BCR-ABL mRNA by reverse transcription PCR in patients undergoing allogeneic bone marrow transplantation for acute lymphoblastic leukemia with a positive Philadelphia chromosome].
    Román J; Castillejo JA; Jiménez A; Maldonado J; Torres A
    Med Clin (Barc); 1999 Dec; 113(20):779-82. PubMed ID: 10680143
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Minimal residual disease in chronic myeloid leukemia in patients with long survival after allogeneic bone marrow transplantation].
    García A; Román J; Brunet S; Andrés P; Baiget M; Torres A
    Med Clin (Barc); 1995 Mar; 104(11):401-6. PubMed ID: 7715257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
    Hess G; Bunjes D; Siegert W; Schwerdtfeger R; Ledderose G; Wassmann B; Kobbe G; Bornhäuser M; Hochhaus A; Ullmann AJ; Kindler T; Haus U; Gschaidmeier H; Huber C; Fischer T
    J Clin Oncol; 2005 Oct; 23(30):7583-93. PubMed ID: 16234522
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients].
    Creutzig U; Ritter J; Zimmermann M; Klingebiel T
    Klin Padiatr; 1996; 208(4):236-41. PubMed ID: 8926689
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Molecular analysis of bcr/abl mRNA in chronic myelogenous leukemia after bone marrow transplantation by using RT-PCR method].
    Nakamura K; Mizutani S; Matsue T
    Rinsho Ketsueki; 1992 Apr; 33(4):436-44. PubMed ID: 1602606
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The significance of serial monitoring of bcr-abl transcripts levels after allogeneic hematopoietic stem cell transplantation in screening chronic myeloid leukemia patients with low relapse].
    Xu LP; Liu KY; Huang XJ; Liu DH; Han W; Chen YH; Wang Y; Liu YR; Qin YZ
    Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):522-5. PubMed ID: 19112914
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Cytogenetic analysis and bcr/abl mRNA detection in chronic myeloid leukemia].
    Yao B; Guo M; Pian H
    Zhonghua Xue Ye Xue Za Zhi; 1999 Mar; 20(3):137-9. PubMed ID: 11601240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.